Explore

Trendline Trendline
Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Enhance Strategic Growth

Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Enhance Strategic Growth

Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Enhance Strategic Growth
Trendline Trendline
Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Drive Strategic Growth

Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Drive Strategic Growth

Zura Bio Appoints Muzammil Mustufa as Chief Business Officer to Drive Strategic Growth
Trendline Trendline
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors
Trendline Trendline
Degron Therapeutics Secures $40 Million to Advance Molecular Glue Degrader Development

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Degrader Development

Degron Therapeutics Secures $40 Million to Advance Molecular Glue Degrader Development
Trendline Trendline
Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors, Signaling Strategic Growth

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors, Signaling Strategic Growth

Anaveon Appoints Thomas P. Mathers as Chair of the Board of Directors, Signaling Strategic Growth
Trendline Trendline
Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials

Curis Reports First Quarter 2026 Financial Results Amid Ongoing Clinical Trials
Trendline Trendline
Hiteck and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026

Hiteck and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026

Hiteck and LexBio Unveil HT016 VAV1 Molecular Glue Degrader at AAI 2026
Trendline Trendline
Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204

Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204

Silexion Therapeutics Initiates GMP Manufacturing for Pancreatic Cancer Drug SIL204
Trendline Trendline
Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026

Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026

Enanta Pharmaceuticals Reports Decreased Net Loss Amid Financial Results for Q2 2026
Trendline Trendline
Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments

Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments

Enanta Pharmaceuticals Reports Q2 2026 Financial Results Highlighting Revenue Growth and Strategic Developments
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
Vertex Pharmaceuticals to Engage in Key Investor Conferences in May 2026

Vertex Pharmaceuticals to Engage in Key Investor Conferences in May 2026

Vertex Pharmaceuticals to Engage in Key Investor Conferences in May 2026